Analysts expect over 2023 decreasing revenue arGEN-X

Next Monday the Belgian arGEN-X will report its past quarters results. For this year arGEN-X 's (located in ) revenue will be around 1.15 billion euros. This is according to the average of the analysts' estimates. This is quite lower than 2022's revenue of 410.75 million euros.

Historical revenues and results arGEN-X plus estimates 2023

The analysts expect for 2023 a net loss of 296 million euros. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a loss per share of 5.1 euros. The price/earnings-ratio therefore equals -86.25.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a good 3.55 percent.

Latest estimates around 482 euros

The most recent recommendations for the biotech company are from KBC Securities, Morgan Stanley and Goldman Sachs .

Based on the current number of outstanding shares arGEN-X 's market capitalization 22.73 billion euros.

At 11.24 the stock trades 1.27 percent higher at 439.9 euros.

Historical stock prices arGEN-X past 17 years

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.